Back to Search
Start Over
Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature
- Source :
- Leukemia Research Reports, Vol 8, Iss C, Pp 21-23 (2017)
- Publication Year :
- 2017
- Publisher :
- Elsevier, 2017.
-
Abstract
- The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact on the feasibility of alloHCT and the optimal timing of administration are limited. Here we present a case of relapsed TP53 mutated CLL treated with ibrutinib as a bridge to alloHCT, discussing risks and benefits of different treatment options in a “real life” situation.
Details
- Language :
- English
- ISSN :
- 22130489
- Volume :
- 8
- Issue :
- C
- Database :
- Directory of Open Access Journals
- Journal :
- Leukemia Research Reports
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.56a6c00de4c74ecf9e079bcf41974f8b
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.lrr.2017.11.001